Literature DB >> 8545119

Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation.

I C Taylor1, S Roy, H E Varmus.   

Abstract

Most receptor tyrosine kinases are activated by dimerization induced by their cognate ligands. Protein S, an abundant serum protein previously shown to be a potent anticoagulation factor, has been proposed to be a ligand for the Sky tyrosine kinase (Stitt et al., 1995). Here we show that Sky, when expressed to high levels, is tyrosine phosphorylated even in the absence of a ligand. Furthermore, a version of Sky (termed Sky delta SS) engineered to be overexpressed in the cytoplasm and thus in a ligand-free environement, can function as a dimeric tyrosine kinase. Sky delta SS can transform RatB1a fibroblasts and thus retains all the properties of the full-length Sky kinase. These data suggest that Sky, when overexpressed either at the cell surface or in the cytoplasm, is competent to form dimers even in the absence of its ligand. We also demonstrate that an isoform of Sky, originally reported as Brt and here termed Sky Isoform I, resides in the cytoplasm. Therefore, the activities of Sky delta SS we describe may reflect those of the naturally occurring Isoform I.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545119

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

Review 2.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 3.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

4.  Hematopoietic progenitor cells grow on 3T3 fibroblast monolayers that overexpress growth arrest-specific gene-6 (GAS6).

Authors:  S P Dormady; X M Zhang; R S Basch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

5.  Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.

Authors:  G C Huang; X Ouyang; R J Epstein
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

6.  Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer.

Authors:  C-W Chien; P-C Hou; H-C Wu; Y-L Chang; S-C Lin; S-C Lin; B-W Lin; J-C Lee; Y-J Chang; H S Sun; S-J Tsai
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

Review 7.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  A genomic screen identifies TYRO3 as a MITF regulator in melanoma.

Authors:  Shoutian Zhu; Heiko Wurdak; Yan Wang; Anna Galkin; Haiyan Tao; Jie Li; Costas A Lyssiotis; Feng Yan; Buu P Tu; Loren Miraglia; John Walker; Fanxiang Sun; Anthony Orth; Peter G Schultz; Xu Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

9.  Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion.

Authors:  M Y Wang; K Koyama; M Shimabukuro; D Mangelsdorf; C B Newgard; R H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

Review 10.  TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system.

Authors:  Angela M Pierce; Amy K Keating
Journal:  Brain Res       Date:  2013-11-01       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.